NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
30/06/2026
Voltar para busca
Dado oficial do USPTO
TARGED TARGETED ENZYME DELIVERY
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
22
Atualização mais recente
30/06/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42
Data de depósito
22/08/2025
Data de registro
30/06/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
30/06/2026
Última transação
30/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
24
Localização do titular
NL
Examinador
HUDSON, TAMARA BREE
Unidade examinadora
L40
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of the word "TARGED" in stylized font wherein the letters "TARG" are in aqua green and the letters "ED" are in dark green, with a dark green arrow forming the middle arm of the "E"; below this word is the wording "TARGETED ENZYME DELIVERY" in stylized grey font.
Titulares e representantes
Titulares
TargED Biopharmaceuticals B.V.
Representantes
Lindsay M.R. Jones
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the treatment of diseases associated with thrombosis; medical preparations for the treatment of diseases associated with thrombosis; dietary supplements for medical purposes; medicinal herbs and medicinal herbal extracts; drugs for medical purposes for the treatment of diseases associated with thrombosispharmaceutical preparations for the prevention and treatment of diseases associated with thrombosis; pharmaceutical preparations being antithrombotic agents; thrombolytic drugs; pharmaceutical preparations being coagulation inhibitors; anticoagulants; pharmaceutical preparations in the nature of platelet aggregation inhibitors; pharmaceutical preparations in the nature of hemostatic agents; pharmaceutical preparationsblood thinners for medical use; therapeutic compounds for diseases associated with thrombosis; pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for blood clotting disorders; injectable or intravenous medicinal solutions for thrombosis-related treatment; medicinal preparations for the treatment of deep vein thrombosis (DVT); medicinal preparations for pulmonary embolism (PE) management; preclinical or clinical trial medicines for thrombosis-related treatment research; pharmaceuticals for vascular diseases
Classe 42
Scientific and technological servicesresearch and design in the field of medicine and pharmaceuticals; research and development services in the field of medicine and pharmaceuticals; scientific research in the nature of conducting laboratory and clinical testing for others; biotechnology research services; pharmaceutical research services; medical and scientific laboratory services; medical research and development services; research and development in the field of thrombosis treatment; pharmaceutical and biotechnology research for antithrombotic drugs; scientific research in the nature of conducting preclinical and clinical trials for others in the field of drugs for diseases associated with thrombosis; d r u g discovery services related to thrombosis; development of biopharmaceuticals for cardiovascular diseases; scientific research in the field of platelet aggregation inhibitors; consultancy services in pharmaceutical research and development; conducting scientific studies related to thrombosis-related and blood clotting disorders; scientific research in the nature of conducting clinical trials for others in the field of thrombosis-related drugs and therapies; design and development of drug efficacy studies for treatment of diseases associated with thrombosis; genetic research and molecular biology research services related to thrombosis; technical data analysis of scientific research and providing temporary use of onlinenon-downloadable computer software for use in modeling in the field of treatment of diseases associated with thrombosis; laboratory research services for thrombosis-related diagnosis and testing; research services related to anticoagulation therapy; research in personalized medicine for patients of diseases associated with thrombosis patients; quality assessmentreference material certification services being the testinganalysis and evaluation of the goods of others to determine conformity with certification standards in the field of treatment of diseases associated with thrombosis treatment; research and development services for biotechnological solutions for diseases associated with thrombosis; scientific advisory and consultation services in thrombosis-related research
Publicações
Histórico de despachos e eventos da marca no USPTO.
22 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
30/06/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/05/2026
PUBO
PUBLISHED FOR OPPOSITION
12/05/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/05/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/04/2026
XAEC
EXAMINER'S AMENDMENT ENTERED
14/04/2026
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
14/04/2026
GNEA
EXAMINERS AMENDMENT E-MAILED
14/04/2026
CNEA
EXAMINERS AMENDMENT -WRITTEN
14/04/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/04/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/04/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/04/2026
RFNT
REFUSAL PROCESSED BY IB
26/02/2026
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
12/02/2026
RFRR
REFUSAL PROCESSED BY MPU
11/02/2026
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
15/01/2026
CNRT
NON-FINAL ACTION WRITTEN
14/01/2026
DOCK
ASSIGNED TO EXAMINER
07/01/2026
MAFR
APPLICATION FILING RECEIPT MAILED
28/11/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
28/11/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
27/11/2025
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace TARGED TARGETED ENZYME DELIVERY ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.